HENDERSON, Nev., April 26, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company is hosting a Capital Markets Day in a hybrid format (in-person and live-webcast) on Thursday, May 11, 2023, at 2 p.m. U.S. Eastern Time. Volition's executive team will be joined by Key Opinion Leaders: Dr. Andy Retter (Intensive Care Consultant) and Veterinary Oncologists, Professor Heather Wilson-Robles and Dr. Sue Ettinger, aka Dr. Sue Cancer Vet.
Event: VolitionRx Limited Capital Markets Day
Date: Thursday, May 11, 2023
Time: 2:00 p.m. Eastern time
In-person Venue: Hamilton Suite, New York Stock Exchange, 11 Wall Street, New York
To attend in person, contact This email address is being protected from spambots. You need JavaScript enabled to view it.
To attend virtually please register HERE
Presentations will cover:
A question-and-answer session with management will follow the prepared remarks and formal presentation.
To attend the event in-person please contact This email address is being protected from spambots. You need JavaScript enabled to view it.
To access the virtual event, register by clicking HERE.
The event will be webcast and the presentations will be posted to Volition's website. A replay will also be made available.
For additional information or questions please contact Investor Relations at This email address is being protected from spambots. You need JavaScript enabled to view it.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com
About Volition
Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. The website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, This email address is being protected from spambots. You need JavaScript enabled to view it., +44 (0)7557 774620
Investor Enquiries:
Scott Powell, Volition, This email address is being protected from spambots. You need JavaScript enabled to view it., +1 (646) 650 1351
| Last Trade: | US$0.47 |
| Daily Change: | -0.03 -5.80 |
| Daily Volume: | 168,301 |
| Market Cap: | US$45.200M |
March 28, 2025 March 21, 2025 March 13, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
